Cirrhosis - Pipeline Review, H2 2014

Date: July 15, 2014
Pages: 67
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CB7F981456AEN
Leaflet:

Download PDF Leaflet

Cirrhosis - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Cirrhosis - Pipeline Review, H2 2014’, provides an overview of the Cirrhosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Cirrhosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cirrhosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cirrhosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Cirrhosis Overview
Therapeutics Development
Pipeline Products for Cirrhosis - Overview
Pipeline Products for Cirrhosis - Comparative Analysis
Cirrhosis - Therapeutics under Development by Companies
Cirrhosis - Therapeutics under Investigation by Universities/Institutes
Cirrhosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Cirrhosis - Products under Development by Companies
Cirrhosis - Products under Investigation by Universities/Institutes
Cirrhosis - Companies Involved in Therapeutics Development
Gilead Sciences, Inc.
Novartis AG
Ocera Therapeutics, Inc.
Hyperion Therapeutics, Inc.
Intercept Pharmaceuticals, Inc.
PharmaIN Corporation
Alfact Innovation
Cirrhosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ornithine phenylacetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glycerol phenylbutyrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALF-5755 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGC Based Natriuretic Peptides - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cirrhosis - Recent Pipeline Updates
Cirrhosis - Dormant Projects
Cirrhosis - Product Development Milestones
Featured News & Press Releases
Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting
Sep 19, 2013: Les Laboratoires Servier Receives CHMP Positive Opinion For Valdoxan
Sep 17, 2013: Vasopressin V2 Receptor Antagonist Samsca 7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
May 02, 2013: Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA
Nov 12, 2012: Hyperion Therapeutics Announces Presentation Of Results From Phase II HALT-HE Study At 63rd Annual Meeting Of AASLD
Nov 09, 2012: Salix Pharma Announces Presentation Of Xifaxan Data At 63rd Annual Meeting Of AASLD
Nov 05, 2011: Janssen Presents New Data On INCIVO At American Association For Society Of Liver Disease Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cirrhosis, H2 2014
Number of Products under Development for Cirrhosis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2014
Cirrhosis - Pipeline by Novartis AG, H2 2014
Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H2 2014
Cirrhosis - Pipeline by Hyperion Therapeutics, Inc., H2 2014
Cirrhosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014
Cirrhosis - Pipeline by PharmaIN Corporation, H2 2014
Cirrhosis - Pipeline by Alfact Innovation, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2014
Cirrhosis - Dormant Projects, H2 2014

LIST OF FIGURES

Number of Products under Development for Cirrhosis, H2 2014
Number of Products under Development for Cirrhosis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

COMPANIES MENTIONED

Gilead Sciences, Inc.
Novartis AG
Ocera Therapeutics, Inc.
Hyperion Therapeutics, Inc.
Intercept Pharmaceuticals, Inc.
PharmaIN Corporation
Alfact Innovation
Skip to top


Primary Biliary Cirrhosis - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 90 pages
Cirrhosis - Pipeline Review, H1 2014 US$ 1,500.00 Feb, 2014 · 49 pages
Liver Cirrhosis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 102 pages
Biliary Cirrhosis - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 75 pages
PharmaIN Corporation - Product Pipeline Review - 2014 US$ 1,200.00 Dec, 2014 · 31 pages

Ask Your Question

Cirrhosis - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: